Aarti Drugs Ltd.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2009

(Rs. In Lacs)

PARTICULARS			For the Quarter Ended	For the Quarter Ended	For the Year ended	For the Year ended	Consolidated For theYear ended
PARTICULARS			31st Mar 2009	31st Mar 2008	31st Mar 2009	31st Mar 2008	31st Mar 2009	31st Mar 2008
1.	(a)	(Net) Sales / Income from operations	10,680	11,005	37,650	31,073	38,212	31,236
	(b)	Other Operating Income	-	-	-	-	-	-
2.	Expenditure
	(a).	(Increase) / Decrease in stock in trade	1,212	1,004	695	(924)	889	(1,038)
	(b).	Consumption of raw materials.	4,651	4,776	21,077	18,259	21,388	18,541
	(c).	Purchase of Traded Goods	1,311	2,322	3,443	3,892	2,522	3,084
	(d).	Employees cost	336	275	1,114	980	1,200	1,054
	(e).	Depreciation	319	252	1,104	963	1,448	1,302
	(f).	Other expenditure	1,534	1,595	5,648	5,119	5,779	5,180
	(g).	Total Expenditure	9,363	10,224	33,081	28,289	33,225	28,123
3.	Profit from Operating before Other Income		1,317	781	4,570	2,783	4,987	3,112
4.	Other Income		1	112	17	184	52	185
5.	Profit before Interest & Exceptional Items		1,318	893	4,587	2,967	5,040	3,297
6.	Interest		508	582	2,272	1,184	2,435	1,288
7.	Profit after Interest but before Exceptional Items		810	311	2,315	1,783	2,604	2,009
8.	Exceptional Items		-	-	-	-	-	-
9.	Profit from Ordinary Activities before Tax		810	311	2,315	1,783	2,604	2,009
10.	Tax Expenses (Includes)		354	124	810	476	847	528
		Provision for Taxation	272	55	540	230	580	256
		Provision for FBT	4	5	15	16	16	17
		Provision for Deffered Taxation	78	65	255	230	251	256
11.	Net profit from ordinary Activities after Tax		456	187	1,505	1,307	1,757	1,481
12.	Extraodinary Item (net of tax expenses )
13.	Net Profit for the period		456	187	1,505	1,307	1,757	1,481
	Less :
	( a)	Minority Interest	-	-	-	-	86	73
	( b)	Adjustments on Consolidation	-	-	-	-	19	12
	( c)	Share of Loss in Associate	-	-	-	-	56	23
	Profit After Consolidation adjustments		456	187	1,505	1,307	1,597	1,374
14.	Paid-up Equity Share Capital of Rs.10/- each.		1,171	1,171	1,171	1,171	1,171	1,171
15.	Reserves & Surplus (excluding revaluation reserves)		-	-	10,827	9,734	11,153	9,982
16.	Basic E P S (in Rs.)		3.90	1.60	12.85	11.17	13.64	11.73
17.	Public Shareholding
		Number of Shares	5495949	6045866	5495949	6045866	5495949	6045866
		Percentage of Total Shareholding	46.94	51.64	46.94	51.64	46.94	51.64
18.	Promoters & Promoter Group Shareholding**
	a)	Pledged/Encumbered
		- Number of Shares	NIL	N.A	NIL	N.A	NIL	N.A
		-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group)	NIL	N.A	NIL	N.A	NIL	N.A
		-Percentage of shares( as a percentage of total sharecapital of the Company)	NIL	N.A	NIL	N.A	NIL	N.A
	b)	Non-encumbered
		- Number of Shares	6212601	N.A	6212601	N.A	6212601	N.A
		-Percentage of shares( as a percentage of total shareholding of promoter and promoter group)	100	N.A	100	N.A	100	N.A
		-Percentage of shares (as a percentage of total sharecapital of the Company)	53.06	N.A	53.06	N.A	53.06	N.A

Notes :

The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 20th May 2009.

The Board of Directors has recommended Dividend of Rs.3 per share (30%) on 1,17,08,550 Equity shares of Rs.10/- each fully paid-up for the Financial year 2008-09

Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

The figures of the previous periods have been regrouped and rearranged wherever necessary.

There were no pending complaints at the beginning of the Quarter. During the quarter one complaint was received and redressed. There were no complaints pending at the end of the quarter.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED